Transthyretin amyloid cardiomyopathy (ATTR‐CM) is a life‐threatening condition with a
heterogeneous clinical presentation. The recent availability of treatment for ATTR‐CM has …

Transthyretin cardiac amyloidosis (ATTR-CA) is an overlooked cause of heart failure, with
substantial morbidity and mortality. The emergence of several novel therapies has fueled the …

With the current advances in imaging technology and changes in patient demographics,
computed tomography (CT) has become an important part of nuclear cardiology practice for …

Nuclear imaging techniques can detect and quantify pathophysiological processes
underlying heart failure, complementing evaluation of cardiac structure and function with …

Transthyretin amyloid cardiomyopathy (ATTR‐CM) is caused by the cardiac deposition of
insoluble amyloid fibrils formed by misfolded transthyretin proteins and is associated with …

Introduction Transthyretin (ATTR) amyloidosis is responsible for the majority of cardiac
amyloidosis (CA) cases and can be reliably diagnosed with bone scintigraphy and the visual …

Amyloidoses are a complex group of clinical diseases that result from progressive organ
dysfunction due to extracellular protein misfolding and deposition. The two most common …

Background Bone scintigraphy imaging is frequently used to investigate patients with
suspected transthyretin cardiac amyloidosis (ATTR-CM). However, the reported accuracy for …

Advances in cancer therapeutics have led to dramatic improvements in survival, now
inclusive of nearly 20 million patients and rising. However, cardiovascular toxicities …

Background Cardiac amyloid quantification could advance early diagnosis of amyloid
cardiomyopathy (CMP) and treatment monitoring. However, current imaging tools are based …